Current Report Filing (8-k)
May 18 2022 - 08:33AM
Edgar (US Regulatory)
0001213660
false
0001213660
2022-05-12
2022-05-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 12, 2022
BIMI International Medical Inc. |
(Exact name of registrant as specified in its charter) |
Delaware |
|
001-34890 |
|
02-0563302 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
9th Floor, Building 2, Chongqing Corporation Avenue,
Yuzhong District, Chongqing, P. R. China |
|
116000 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (8604) 1182209211
Not Applicable |
(Former name or former address, if changed since last report) |
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant
to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common stock, $0.001 par value |
|
BIMI |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 12, 2022, the board of directors (the “Board”)
of BIMI International Medical Inc. (the “Company”) elected Ms. Sammi Earn Seok Ang as an independent director of the Company
effective immediately to fill a vacancy that recently occurred as the result of the resignation
of a director.
Ms. Seok Ang has worked at Pacific Rainbow International
In, as a buyer of dietary nutritional raw materials since October 2017. From Dec 2013 to May 2016, she worked at M/A-COM Technology Solutions
Holdings, Inc. as a Logistics Analyst. From Dec 2012 to Dec 2013, she worked at Mindspeed Technologies, Inc., a semiconductor manufacturer
as a buyer/planner. From Feb 2012 to Jul 2012, she worked at Paper Mart, an industrial & retail packaging company as a buyer. From
Jan 2008 to July2010, she worked at RJ Sports, a softgoods importer/wholesaler/manufacturer of golf bags and accessories as a product
manager. Ms. Seok Ang holds two Bachelor’s degrees in International Business – Management and in Computer Information Systems
Track – Client-Server and a Masters’ degree in Business Administration – Logistics and Transportation from Missouri
State University.
On May 11, 2022, Mr. Tiewei Song resigned from
his position as President of the Company, effective immediately. Mr. Song will continue to serve as Chief Executive Officer of the
Company.
On May 12, 2022, the Board appointed Mr. Fnu Oudom
to serve as Chairman of the Board and President of the Company, effective immediately. A copy of the press release announcing the appointment
of Mr. Fnu Oudom as Chairman and President is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated by reference
herein.
Item 9.01 Financial Statements and Exhibits.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: May 18, 2022 |
BIMI International Medical Inc. |
|
|
|
|
By: |
/s/ Tiewei Song |
|
Name: |
Tiewei Song |
|
Title: |
Chief Executive Officer |
2
BIMI International Medical (NASDAQ:BIMI)
Historical Stock Chart
From Feb 2024 to Mar 2024
BIMI International Medical (NASDAQ:BIMI)
Historical Stock Chart
From Mar 2023 to Mar 2024